Vebreltinib plus EGFR-TKI for EGFR-mutated NSCLC with MET-driven resistance: A real-world study of Chinese patients.

vebreltinib (APL-101) - Apollomics

http://www.ncbi.nlm.nih.gov/pubmed/42068890

Haibo Wang; Haipeng Xu; Kan Jiang; Wei Zou; Weijin Xiao; Yanyu Cai; Yiquan Xu; Yunjian Huang; Zhangzhou Huang; Zhiyong He

May 3, 2026